Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Hold” from Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has been assigned a consensus rating of “Hold” from the fourteen brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $40.70.

Several equities research analysts have recently issued reports on the stock. Lifesci Capital lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Guggenheim lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Finally, B. Riley Financial lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 41,076 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares of the company’s stock, valued at $1,735,805.25. This represents a 52.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 309,112 shares of company stock valued at $8,424,535. 4.09% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $36,000. T. Rowe Price Investment Management Inc. grew its stake in Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after buying an additional 1,516 shares in the last quarter. Wells Fargo & Company MN grew its stake in Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares in the last quarter. Finally, Knott David M Jr purchased a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $100,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Trading Down 0.0%

NASDAQ:CNTA opened at $39.59 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The firm has a market cap of $5.91 billion, a price-to-earnings ratio of -22.12 and a beta of 1.13. Centessa Pharmaceuticals has a 52 week low of $10.95 and a 52 week high of $40.26. The firm has a 50-day moving average price of $35.27 and a two-hundred day moving average price of $28.82.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). On average, equities analysts expect that Centessa Pharmaceuticals will post -1.65 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.